GENTAUR
+32 1658 9045
or
0032 (0)16 41 44 07
+32 1650 9045
[email protected]
Av. de l' Armée 68
B-1040 Brussels
BELGIUM

France
tel 01 43 25 01 50
fax01 43 25 01 60
9, rue Lagrange
75005 Paris

Italia
tel 02 36 00 65 93
fax 02 36 00 65 94
20135 Milano

Deutschland
tel +32 1658 9045
fax +32 1650 9045

Polska
Tel 058 710 33 44
Fax 00 32 16 50 90 45
ul. Grunwaldzka 88A/2
81-771 Sopot

日本
tel +81 78 386 0860
fax +81 78 306 0296
Minaatojimaminami-manchi
Chuo-ku, Kobe
065-0047


Österreich
+43720880899
Canada Montreal
+15149077481
Česká republika Praha
+420246019719
Danmark
+4569918806
Finland Helsset
+358942419041
Ελλάς Αθήνα
+302111768494
Magyarország Budapest
+3619980547
Ireland Dublin
+35316526556
Luxembourg
+35220880274
Nederland
+31208080893
Norge Oslo
+4721031366
Polska Warszawa
+48223988221
Sverige Stockholm
+46852503438
Schweiz Züri
+41435006251
US New York
+17185132983
Other Countries
0032 (0)16 41 44 07
|
|
| |
Recombinant Human Interleukin-10 (IL10)
(Cat. No.: C027)
Cat.
No.: C027
1.5 x 106 IU/mg
Recombinant Human Interleukin-10 (IL10)
50ug / 195 Euro
1 mg
1450 Euro
Background:
Interleukin-10 is produced
by murine T-cells following their
stimulation by lectins. The main source
for B-cell-derived Interleukin-10 in
mice is Ly-1 B-cells that express CD5
and CD11. Murine keratinocytes also
produce IL10.
In humans IL-10 is produced by
activated CD8 (+) peripheral blood
T-cells, by T-helper CD4 (+) T-cell
clones (resembling Th0, Th1, and Th2)
after both antigen-specific and
polyclonal activation, by B-cell
lymphomas, and by monocytes following
cell activation by bacterial
lipopolysaccharides and mast cells.
B-cell lines derived from patients with
acquired immunodeficiency syndrome and
Burkitt's lymphoma constitutively
secrete large quantities of IL-10 into
the conditioned medium. The synthesis of
IL-10 by monocytes is inhibited by IL-4
and IL-10.
Description:
Recombinant Human IL-10
produced in E. coli is a single,
non-glycosylated polypeptide chain
containing 160 amino acids and having a
molecular mass of 18648 Dalton.
Quality Control:
Biological Activity: The
ED50 as determined by the dose-dependant
co-stimulation with murine IL-4 of MC-9
cells was found to be < 2ng/ml,
corresponding to a Specific Activity of
1.5 x 106 IU/mg.
Purity: Greater than
98.0% as determined by:
(a) Analysis by
RP-HPLC.
(b) Anion-exchange
FPLC.
(c) Analysis by
reducing and non-reducing SDS-PAGE
Silver Stained gel.
Amino-Acid Sequence: The
sequence of the first five N-terminal
amino acids was determined and was found
to be Ser-Pro-Gly-Gln-Thr.
Endotoxin: Less than 0.1
ng/µg (IEU/µg) of rHuIL-10.
Formulation: The protein was
lyophilized from a concentrated (1mg/ml)
solution containing 60mM PBS pH-6.5 and
100mM NaCl.
Storage: Lyophilized rHuIL-10
although stable at room temperature for
3 weeks, should be stored desiccated
below -18oC. Upon
reconstitution rHuIL-10 should be stored
at 4oC between 2-7 days and
for future use below -18oC.
For long-term storage it is recommended
to add a carrier protein (0.1% HSA or
BSA).
Please avoid freeze-thaw
cycles.
Reconstitution: It is recommended
to reconstitute the lyophilized rHuIL-10
in sterile 18M¦¸-cm H2O not
less than 100µg/ml, which can then be
further diluted to other aqueous
solutions.
Latest Publications:
1: Basic Clin Pharmacol Toxicol 2007
May;Vol 100(5)
Effect of Interleukin-10 on Tissue
Damage Caused by Organophosphate
Poisoning.
[Abstract]
Organophosphate poisoning is a common
cause of severe morbidity and mortality
among patients admitted to emergency
departments. Tissue damages as a
consequence of organophosphate poisoning
are frequently reported, but preventing
this potentially severe complication has
not been the subject of much research.
We tested whether interleukin-10, a
cytoprotective agent, could prevent or
diminish pathological signs of tissue
damages caused by organophosphate
poisoning. Thirty rats were divided into
three equal groups (n = 10). Group 1
(sham) did not receive any agent during
the experiment. Group 2 (control)
received 0.8 g/kg of fenthion
intraperitoneally, followed by 6 ml/kg
of intraperitoneal normal saline 30 min.
and 3 hr later. Group 3 (treatment)
received 0.8 g/kg of fenthion
intraperitoneally, followed by 2
microg/kg of interleukin-10
intraperitoneally 30 min. and 3 hr
later. All rats were killed under
anaesthesia after 6 hr and tissue
samples were obtained from liver,
kidneys and lungs. Even organophosphate
poisonings do not cause significant
clinical problems; several degrees of
damages could be observed in liver,
kidneys and lungs. These damages could
be reduced by interleukin-10 treatment.
2: Nihon Arukoru Yakubutsu Igakkai
Zasshi 2007
Feb;Vol 42(1)
Saturated and monounsaturated fatty
acids increase interleukin-10 production
in rat hepatocytes.
[Abstract]
Interleukin-10 (IL-10) is a potent
anti-inflammatory cytokine, but it still
remains unknown whether saturated or
unsaturated fatty acid affects IL-10
production in hepatocytes that
contribute to lipid metabolism. Primary
rat hepatocyte cultures were treated
with different fatty acids (18:0 stearic
acid, 18:1 oleic acid; 18:2 linoleic
acid, 18:3 linolenic acid) at 300 microM
for 24 hours. The concentrations of
IL-2, IL-10, GM-CSF and IFN-gamma in the
medium were detected by multiplex
cytokine array. IL-10 was significantly
increased with treatment of stearic acid
and oleic acid. Production of IL-10 by
saturated and monounsaturated fatty
acids in hepatocytes may be one of the
reasons why the lard oil had less
inflammation in the hepatic steatosis
animal models.
3: Cytokine 2007 Apr;
Serum levels of Interleukin-15 and
Interleukin-10 and their correlation
with proliferating cell nuclear antigen
in multiple myeloma.
[Abstract] In order
to determine prognostic factors
characterizing multiple myeloma (MM)
cell kinetics, bone marrow proliferative
activity and serum Interleukin-10
(IL-10), and Interleukin-15 (IL-15)
levels were measured in 40 newly
diagnosed MM patients, compared with
10-age and sex-matched-healthy controls.
Cell proliferation was evaluated by
employing a monoclonal antibody directed
against the proliferating cell nuclear
antigen (PCNA), whereas IL-10 and IL-15
were measured with quantitative sandwich
enzyme immunoassay methods. IL-15, IL-10
and PCNA were higher in the patient
group than in controls (P<0.001). IL-10
levels, and PCNA increased significantly
with increasing Durie-Salmon disease
stage (I-III, P<0.002, and P=0.001,
respectively). Serum IL-15 levels in MM
stage III patients were elevated in
comparison with stages I and II, the
difference however, did not reach
statistical significance. There was a
significant positive correlation between
serum IL-15 and IL-10 levels (r: 0.372,
P<0.01), and between serum IL-10 and
PCNA (r: 0.608, P<0.0001), as well as a
positive correlation of serum IL-15 with
PCNA, which marginally failed to reach
statistical significance. Serum IL-15
levels are elevated in MM patients,
increase with advancing stage, and
correlate with Il-10 and PCNA. These
proliferative factors may be useful in
assessing disease progression in MM.
4: J Immunol 2007 May;Vol
178(9)
Cutting Edge: Lipopolysaccharide Induces
IL-10-Producing Regulatory CD4+ T Cells
That Suppress the CD8+ T Cell Response.
[Abstract] TLR
ligands are potent activators of
dendritic cells and therefore function
as adjuvants for the induction of immune
responses. We analyzed the capacity of
TLR ligands to enhance CD8(+) T cell
responses toward soluble protein Ag.
Immunization with OVA together with LPS
or poly(I:C) elicited weak CD8(+) T cell
responses in wild-type C57BL/6 mice.
Surprisingly, these responses were
greatly increased in mice lacking CD4(+)
T cells indicating the induction of
regulatory CD4(+) T cells. In vivo,
neutralization of IL-10 completely
restored CD8(+) T cell responses in
wild-type mice and OVA-specific IL-10
producing CD4(+) T cells were detected
after immunization with OVA plus LPS.
Our study shows that TLR ligands not
only activate the immune system but
simultaneously induce Ag specific,
IL-10-producing regulatory Tr1 cells
that strongly suppress CD8(+) T cell
responses. In this way, excessive
activation of the immune system may be
prevented.
Domain Info

GeneBank Entry:
NM_000572
Protein Accession No.:
NP_000563
Protein Sequence:
SPGQG TQSEN
SCTHF PGNLP NMLRD LRDAF SRVKT FFQMK
DQLDN LLLKE SLLED FKGYL GCQAL SEMIQ
FYLEE VMPQA ENQDP DIKAH VNSLG ENLKT
LRLRL RRCHR FLPCE NKSKA VEQVK NAFNK
LQEKG IYKAM SEFDI FINYI EAYMT MKIRN
Transcript Info

|
|
|
|
|
|